NCT05458570 (BC) is a clinical trial of Breast Cancer positive patients in Breast Cancer, sponsored by Bahria University.

Who is sponsoring NCT05458570?

NCT05458570 is sponsored by Bahria University.

What drugs are being tested in NCT05458570?

Interventions in NCT05458570: Breast Cancer positive patients.

What condition does NCT05458570 study?

NCT05458570 studies Breast Cancer.

Is NCT05458570 still recruiting?

NCT05458570 is currently completed. Last updated 14 July 2022.

Last reviewed 2022-07-14 · How we verify

NCT05458570: BC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ethnic Predisposition, Risk Factors & Breast Cancer Presentation.

Completed Last updated 14 July 2022

What this trial tests

trial testing Breast Cancer positive patients in Breast Cancer in 500 participants. Completed in 31 December 2020.

Timeline

1 January 2010

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Bahria University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 January 2010
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Pakistan

Drugs / interventions tested

Breast Cancer positive patients

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Bahria University

Who can join

Adults 20 to 85, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breast cancer, a leading cause of mortality among females, has been the center of research for many decades. Work is in progress to further advance the research worldwide and in our region. This study is conducted to look into regional ethical predilection, clinical presentation/stage, pathological subtypes \& risk factors of BC among patients of Karachi, with the aim of proposing a ground to policy making regarding protocol setting for screening and management of BC for our region.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ethnic predisposition, risk factors and breast cancer presentation; a 10-year data. Single centered prospective cohort study from Karachi.
Sultan N, Memon SA, Mooghal M, Wali S, et al · · 2022 · cited 1× · PMID 36268285 · DOI 10.1016/j.amsu.2022.104612

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Bahria University trials

Trials by the same sponsor.

NCT07385781 — Psychosomatic Symptoms in Patients With Myofascial Pain and Temporomandibular Joint Dysfunction · not yet recruiting
NCT07379983 — Evaluating the Effectiveness of Print Based Environmental Health Intervention Education Among School Going Adolescents o · NA · not yet recruiting
NCT07452913 — Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes · Phase 4 · enrolling by invitation
NCT07255820 — Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol · Phase 4 · not yet recruiting
NCT07375082 — Rehabilitation Approaches Used in Total Knee Replacement · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05458570 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bahria University
Last refreshed: 14 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05458570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing